Dr Reddy’s Laboratories reported consolidated revenue of INR eight thousand seven hundred twenty seven crore in the third quarter of financial year twenty six, registering year on year growth. However, the company’s net profit declined by fourteen percent compared to the same period last year, mainly due to margin pressure and weaker performance in key markets.

During the quarter, earnings before interest, tax, depreciation and amortisation declined on a year on year basis, while gross margins narrowed. This was largely driven by pricing pressure and lower sales in the North American generics business. The company stated that reduced contribution from certain key products weighed on overall profitability, even as steady growth in India, Europe and other emerging markets helped support revenues.

Dr Reddy’s continued to invest in new product launches, biosimilar development and pipeline expansion during the quarter. Management reiterated its focus on improving operational efficiency, maintaining disciplined capital allocation and strengthening the core business to drive long term growth in a challenging global pricing environment.